Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tolazamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | ALB | P02768 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.65 |
| ▸ | THRB | P10828 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | HTR2A | P28223 | 1/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolazamide SCHEMBL2534564 | 0.96 | ALDH1A1 (0.70) | ALDH1A1LMNACYP2C9TSHRCYP3A4 | |
| Tolazamide SCHEMBL992662 | 0.93 | ALDH1A1 (0.75) | ALDH1A1LMNACYP2C9TSHRCYP3A4 | |
| Glypinamide SCHEMBL5243890 | 0.90 | ALDH1A1 (0.59) | ALDH1A1LMNACYP2C9TSHRCYP3A4 | |
| Tolbutamide SCHEMBL12498646 | 0.89 | ALDH1A1 (0.82) | ALDH1A1LMNACYP2C9TSHRCYP3A4 | |
| Tolbutamide SCHEMBL1536920 | 0.80 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2C9TSHRCYP3A4 | |
| Tolbutamide SCHEMBL15918 | 0.80 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2C9TSHRCYP3A4 | |
| Glypinamide SCHEMBL343885 | 0.80 | ALDH1A1 (0.74) | ALDH1A1LMNACYP2C9TSHRCYP3A4 | |
| Tolazamide SCHEMBL13725632 | 0.80 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2C9TSHRCYP3A4 | |
| Tolazamide SCHEMBL34417 | 0.80 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2C9TSHRCYP3A4 | |
| Tolbutamide SCHEMBL7551276 | 0.79 | ALDH1A1 (0.97) | ALDH1A1LMNACYP2C9TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430011-A1 | 5-PYRIDIN-3-YL-1,3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | Novartis AG (CH) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010130794-A1 | 5-PYRIDIN-3-YL-1,3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | NOVARTIS AG (CH) | 2010-11-18 | — | — | WO | disclosed |
| EP-1836665-A2 | METHOD FOR CUSTOMIZED DISPENSING OF VARIABLE DOSE DRUG COMBINATION PRODUCTS FOR INDIVIDUALIZING OF THERAPIES | SmithKline Beecham Corporation (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006055886-A2 | METHOD FOR CUSTOMIZED DISPENSING OF VARIABLE DOSE DRUG COMBINATION PRODUCTS FOR INDIVIDUALIZING OF THERAPIES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-26 | — | — | WO | disclosed |